<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024448</url>
  </required_header>
  <id_info>
    <org_study_id>PB_2020-00001</org_study_id>
    <nct_id>NCT05024448</nct_id>
  </id_info>
  <brief_title>Glucocorticosteroid Treatment in Acute Unilateral Vestibulopathy (Vestibular Neuronitis)</brief_title>
  <official_title>Glucocorticosteroid Treatment in Acute Unilateral Vestibulopathy, a Multicentric, Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The vestibular system is a part of the inner ear and functions as a motion sensor. It&#xD;
      provides the central nervous system with information about changes of the head position. This&#xD;
      information is essential for the proper functioning of the balance system. In particular, it&#xD;
      ensures effective postural control and gaze stabilization. Abrupt vestibular deficit is&#xD;
      defined as a sudden loss of the vestibular function. In the acute phase the patient presents&#xD;
      mainly with intense rotatory vertigo and instability, most often accompanied by nausea. The&#xD;
      symptoms are exacerbated by head movements. The diagnosis is made by observation of a&#xD;
      spontaneous nystagmus, measurement of a pathological head impulse test and an asymmetric&#xD;
      response to caloric tests, in the absence of other neurological symptoms. Although the&#xD;
      etiology is unknown, it could be of viral or vascular origin. Symptoms usually regress within&#xD;
      a few days or weeks. Vestibular function recovers in about half of the cases, in the other&#xD;
      half a central compensation process is set up. The benefit of a 3-week course of&#xD;
      corticosteroids has been demonstrated in one study. The dosage has been debated. The aim of&#xD;
      this study is to demonstrate the benefit of a 10-day course of oral corticosteroids. The&#xD;
      primary objective is to demonstrate a significant reduction in the rate of asymmetry of&#xD;
      caloric response and the secondary objective is to demonstrate a significant reduction in the&#xD;
      impact of symptoms assessed with the Dizziness Handicap Inventory (DHI) score at 1 year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2013</start_date>
  <completion_date type="Actual">June 9, 2021</completion_date>
  <primary_completion_date type="Actual">June 9, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bithermal calorics asymetry</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bithermal calorics asymetry</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bithermal calorics asymetry</measure>
    <time_frame>Day 365</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dizziness Hanidcap Inventory (Questionnaire)</measure>
    <time_frame>Day 1, Day 21, Day 365</time_frame>
    <description>min: 0 / max:100, higher score is worse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Acute Peripheral Vestibulopathy</condition>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone, 60mg/d, for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>oral administration, 60mg/d for 10d</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Medical History :&#xD;
&#xD;
          -  severe and prolonged rotatory vertigo;&#xD;
&#xD;
          -  acute onset, subacute, within 3 days;&#xD;
&#xD;
          -  nausea ;&#xD;
&#xD;
          -  imbalance.&#xD;
&#xD;
        Physical examination :&#xD;
&#xD;
          -  spontaneous nystagmus beating towards the healthy ear (fast phase);&#xD;
&#xD;
          -  no evidence of central vestibular lesion;&#xD;
&#xD;
          -  Head impulse test abnormal, at least for the lateral semicircular canal (in some&#xD;
             cases, the sign is only detectable for the 2 vertical semicircular canals with&#xD;
             specific equipment, mostly not available in current practice);&#xD;
&#xD;
          -  areflexia or hyporeflexia (asymetry &gt; 70% calculated according to the classical&#xD;
             Jongkees formula [slow phase velocity of the nystagmus in response to caloric&#xD;
             stimulation at (right at 30°C + right at 44°C) - ( left at 30°C + left at 44°C ) /&#xD;
             (right 30°C + left 30°C + right 44°C + left at 44°C) x 100], in the caloric test (10&#xD;
             cc in 20 s, at 30 and 44° C)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of vestibular disorders other than benign paroxysmal positionning vertigo&#xD;
             (BPPV);&#xD;
&#xD;
          -  symptoms lasting more than 3 days;&#xD;
&#xD;
          -  cochlear symptoms (deafness before, during or after vertigo);&#xD;
&#xD;
          -  central oculomotor dysfunction;&#xD;
&#xD;
          -  central vestibular dysfunction;&#xD;
&#xD;
          -  signs of brain dysfunction (e.g. epilepsy);&#xD;
&#xD;
          -  MRI (if done) abnormal central vestibular pathways;&#xD;
&#xD;
          -  psychiatric disease (history of psychiatric disease);&#xD;
&#xD;
          -  glaucoma ;&#xD;
&#xD;
          -  acute infection (herpes simplex, herpes zoster, corneal herpes, chicken pox,&#xD;
             tuberculosis);&#xD;
&#xD;
          -  patients already on corticosteroids;&#xD;
&#xD;
          -  severe diabetes (fasting blood glucose &gt; 7 mmol/l);&#xD;
&#xD;
          -  Severe hypertension (systolic &gt;180; diastolic &gt; 110);&#xD;
&#xD;
          -  contraindications to glucocorticoids (peptic ulceration, osteoporosis confirmed by&#xD;
             bone density tests or pathological fractures);&#xD;
&#xD;
          -  allergy to glucocorticoids or mannitol&#xD;
&#xD;
          -  malignant disease;&#xD;
&#xD;
          -  cardiac disease (recent myocardial infarction, heart failure);&#xD;
&#xD;
          -  liver dysfunction (cirrhosis)&#xD;
&#xD;
          -  renal insufficiency;&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Nils Guinand</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vestibular Neuronitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

